Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review

Journal of Clinical Medicine - Tập 10 Số 5 - Trang 1085
Jacques Donnez1,2, Marie‐Madeleine Dolmans3,4
1Société de Recherche pour l’Infertilité (SRI), 143 Avenue Grandchamp, 1150 Brussels, Belgium
2Université catholique de Louvain, 1200 Brussels, Belgium
3Gynecology Department, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium
4Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium;

Tóm tắt

Background: The first objective of this review was to present, based on recent literature, the most frequently applied medical options (oral contraceptive pills (OCPs) and progestogens) for the management of symptomatic endometriosis, and evaluate their effectiveness in treating premenopausal women with endometriosis-associated pelvic pain, dysmenorrhea, non-menstrual pelvic pain and dyspareunia. The second objective was to review the concept of progesterone resistance and newly available treatment options. Methods: We reviewed the most relevant papers (n = 73) on the efficacy of OCPs and progestogens as medical therapy for endometriosis, as well as those on progesterone resistance and new medical alternatives (oral gonadotropin-releasing hormone (GnRH) antagonist). Eleven papers, essentially reviews, were selected and scrutinized from among 94 papers discussing the concept of progesterone resistance. Results: Having reviewed the most significant papers, we can confirm that OCPs and progestogens are effective in two-thirds of women suffering from endometriosis, but that other options are required in case of failure (in one-third of women due to progesterone resistance) or intolerance to these compounds. It is clear that there is a need for effective long-term oral treatment capable of managing endometriosis symptoms, while mitigating the impact of side effects. Biochemical, histological and clinical evidence show that estrogens play a critical role in the pathogenesis of endometriosis, so lowering levels of circulating estrogens should be considered an effective medical approach. The efficacy of three oral GnRH antagonists is discussed on the basis of published studies. Conclusion: There is a place for GnRH antagonists in the management of symptomatic endometriosis and clinical trials should be conducted, taking into account the different phenotypes in order to propose novel algorithms.

Từ khóa


Tài liệu tham khảo

Donnez, 2002, The efficacy of medical and surgical treatment of endometriosis-associated infertility: Arguments in favour of a medico-surgical approach, Hum. Reprod. Update., 8, 89, 10.1093/humupd/8.1.89

Nisolle, 1997, Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities, Fertil. Steril., 68, 585, 10.1016/S0015-0282(97)00191-X

Giudice, 2010, Clinical practice. Endometriosis, N. Engl. J. Med., 362, 2389, 10.1056/NEJMcp1000274

Ferrero, 2018, Current and emerging treatment options for endometriosis, Expert Opin. Pharmacother., 19, 1109, 10.1080/14656566.2018.1494154

Vercellini, 2016, Estrogen-progestins and progestins for the management of endometriosis, Fertil. Steril., 106, 1552, 10.1016/j.fertnstert.2016.10.022

Vercellini, 2018, Medical treatment of endometriosis-related pain, Best Pr. Res. Clin. Obstet. Gynaecol., 51, 68, 10.1016/j.bpobgyn.2018.01.015

Practice Committee of the American Society for Reproductive Medicine (2014). Treatment of pelvic pain associated with endome-triosis: A committee opinion. Fertil. Steril., 101, 927–935.

Dunselman, 2014, ESHRE guideline: Management of women with endometriosis, Hum. Reprod., 29, 400, 10.1093/humrep/det457

American College of Obstetricians and Gynecologists (2010). Management of endometriosis. ACOG practice bulletin no. 114. Obstet. Gynecol., 116, 223–236.

Leyland, 2010, Endometriosis: Diagnosis and management, J. Obstet. Gynecol. Can., 32, S1, 10.1016/S1701-2163(16)34589-3

Surrey, 2020, Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database, Clinicoecon Outcomes Res., 12, 473, 10.2147/CEOR.S264905

Soliman, 2017, The burden of endometriosis symptoms on health-related quality of life in women in the United States: A cross-sectional study, J. Psychosom. Obstet. Gynecol., 38, 238, 10.1080/0167482X.2017.1289512

Soliman, 2016, The direct and indirect costs associated with endometriosis: A systematic literature review, Hum. Reprod., 31, 712, 10.1093/humrep/dev335

Bulun, 2010, 17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis, Semin. Reprod. Med., 28, 44, 10.1055/s-0029-1242992

Bulun, 2019, Endometriosis, Endocr. Rev., 40, 1048, 10.1210/er.2018-00242

Yilmaz, 2019, Endometriosis and nuclear receptors, Hum. Reprod. Update, 25, 473, 10.1093/humupd/dmz005

Attia, 2000, Progesterone receptor isoform a but not b is expressed in endometriosis1, J. Clin. Endocrinol. Metab., 85, 2897

Bulun, 2006, Progesterone resistance in endometriosis: Link to failure to metabolize estradiol, Mol. Cell. Endocrinol., 248, 94, 10.1016/j.mce.2005.11.041

Han, 2015, Estrogen receptor b modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis, Cell, 163, 960, 10.1016/j.cell.2015.10.034

Pavone, 2010, Altered retinoid uptake and action contributes to cell survival in endometriosis, J. Clin. Endocrinol. Metab., 95, E300, 10.1210/jc.2010-0459

Pavone, 2011, Endometriosis expresses a molecular pattern consistent with decreased retinoid uptake, metabolism and action, Hum. Reprod., 26, 2157, 10.1093/humrep/der172

Patel, 2017, Progesterone resistance in endometriosis: Origins, consequences and interventions, Acta Obstet. Gynecol. Scand., 96, 623, 10.1111/aogs.13156

Gargett, 2014, Potential role of endometrial stem/progenitor cells in the pathogenesis of early-onset endometriosis, Mol. Hum. Reprod., 20, 591, 10.1093/molehr/gau025

Ober, 1955, Observations on the endometrium and ovary in the newborn, Pediatrics, 16, 445, 10.1542/peds.16.4.445

Brosens, 2015, The endometrium from the neonate to the adolescent, J. Matern. Neonatal Med., 29, 1195, 10.3109/14767058.2015.1040756

Signorile, 2011, Embryologic origin of endometriosis: Analysis of 101 human female fetuses, J. Cell. Physiol., 227, 1653, 10.1002/jcp.22888

Donnez, 2002, Iron overload in the peritoneal cavity of women with pelvic endome-triosis, Fertil. Steril., 78, 712, 10.1016/S0015-0282(02)03346-0

Dolmans, 2002, Potential involvement of hemoglobin and heme in the pathogenesis of peritoneal endometriosis, Fertil. Steril., 77, 561, 10.1016/S0015-0282(01)03211-3

Lousse, 2012, Peritoneal endometriosis is an inflam-matory disease, Front. Biosci. Elite Ed., 4, 23, 10.2741/e358

Donnez, 2016, Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis, Fertil. Steril., 106, 1011, 10.1016/j.fertnstert.2016.07.1075

Agarwal, 2012, The effects of oxidative stress on female reproduction: A review, Reprod. Biol. Endocrinol., 10, 49, 10.1186/1477-7827-10-49

Lousse, 2009, Iron storage is significantly increased in peritoneal macrophages of endometriosis patients and correlates with iron overload in peritoneal fluid, Fertil. Steril., 91, 1668, 10.1016/j.fertnstert.2008.02.103

Patel, 2014, Role of nuclear progesterone receptor isoforms in uterine pathophysiology, Hum. Reprod. Updat., 21, 155, 10.1093/humupd/dmu056

Lousse, 2010, Involvement of the nuclear factor-κB pathway in the pathogenesis of endometriosis, Fertil. Steril., 94, 1985, 10.1016/j.fertnstert.2010.01.013

Simpson, 2003, Genetics of endometriosis, Obstet. Gynecol. Clin. North Am., 30, 21, 10.1016/S0889-8545(02)00051-7

Koninckx, 2019, Pathogenesis of endometriosis: The genet-ic/epigenetic theory, Fertil. Steril., 111, 327, 10.1016/j.fertnstert.2018.10.013

Zubrzycka, A., Zubrzycki, M., Perdas, E., and Zubrzycka, M. (2020). Genetic, epigenetic, and steroidogenic modulation mechanisms in en-dometriosis. J. Clin. Med., 9.

Neal, 2020, Expression of stromal progesterone receptor and differential methylation patterns in the endometrium may correlate with response to progesterone therapy in endometrial complex atypical hyperplasia, Reprod. Sci., 27, 1778, 10.1007/s43032-020-00175-w

Wu, 2005, Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis, Am. J. Obstet. Gynecol., 193, 371, 10.1016/j.ajog.2005.01.034

Cakmak, 2010, Molecular mechanisms of treatment resistance in endometriosis: The role of progesterone–hox gene interactions, Semin. Reprod. Med., 28, 69, 10.1055/s-0029-1242996

Ding, 2010, Dioxin and endometrial progesterone resistance, Semin. Reprod. Med., 28, 59, 10.1055/s-0029-1242995

Heilier, 2008, Organochlorines and endometriosis: A mini-review, Chemosphere, 71, 203, 10.1016/j.chemosphere.2007.09.044

Heilier, 2004, Increased serum polychlorobiphenyl levels in Belgian women with adenomyotic nodules of the rectovaginal septum, Fertil. Steril., 81, 456, 10.1016/j.fertnstert.2003.07.011

Barragan, 2016, Human endometrial fibroblasts derived from mesenchymal progenitors inherit progesterone resistance and acquire an inflammatory phenotype in the endometrial niche in endometriosis, Biol. Reprod., 94, 118, 10.1095/biolreprod.115.136010

Canis, 1997, Revised American Society for Reproductive Medicine classification of endometriosis: 1996, Fertil. Steril., 67, 817, 10.1016/S0015-0282(97)81391-X

Donnez, 1996, Stereometric evaluation of peritoneal endometriosis and endometriotic nodules of the rectovaginal septum, Hum. Reprod., 11, 224, 10.1093/oxfordjournals.humrep.a019024

Donnez, 1996, Peritoneal endometriosis and “endometriotic” nodules of the rectovaginal septum are two different entities, Fertil. Steril., 66, 362, 10.1016/S0015-0282(16)58501-X

Donnez, 1998, Vascular endothelial growth factor (VEGF) in endometriosis, Hum. Reprod., 13, 1686, 10.1093/humrep/13.6.1686

Khan, 2004, Higher activity by opaque endometriotic lesions than nonopaque lesions, Acta Obstet. Gynecol. Scand., 83, 375, 10.1111/j.0001-6349.2004.00229.x

Hogg, 2020, Endometriosis-associated macrophages: Origin, phenotype, and function, Front. Endocrinol., 11, 7, 10.3389/fendo.2020.00007

Redwine, 2002, Was Sampson wrong?, Fertil. Steril., 78, 686, 10.1016/S0015-0282(02)03329-0

Vercellini, 2017, Role of medical therapy in the management of deep rectovaginal endometriosis, Fertil. Steril., 108, 913, 10.1016/j.fertnstert.2017.08.038

Koninckx, 2012, Deep endometriosis: Definition, diagnosis, and treatment, Fertil. Steril., 98, 564, 10.1016/j.fertnstert.2012.07.1061

Donnez, O., and Donnez, J. (2020). Deep endometriosis: The place of laparoscopic shaving. Best Pr. Res. Clin. Obstet. Gynaecol.

Donnez, 1995, Surgery: Rectovaginal septum, endometriosis or adenomyosis: Laparoscopic management in a series of 231 patients, Hum. Reprod., 10, 630, 10.1093/oxfordjournals.humrep.a136001

Reis, 2020, Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure, Hum. Reprod. Updat., 26, 565, 10.1093/humupd/dmaa009

Barra, 2019, A comprehensive review of hormonal and biological therapies for endometriosis: Latest developments, Expert Opin. Biol. Ther., 19, 343, 10.1080/14712598.2019.1581761

Flores, 2018, Progesterone receptor status predicts response to progestin therapy in endome-triosis, J. Clin. Endocrinol. Metab., 103, 4561, 10.1210/jc.2018-01227

Vercellini, 2018, Management of endometriosis: Toward value-based, cost-effective, affordable care, J. Obstet. Gynaecol. Can., 40, 726, 10.1016/j.jogc.2017.07.011

Vercellini, 2018, A stepped-care approach to symptomatic endometriosis management: A participatory research initiative, Fertil. Steril., 109, 1086, 10.1016/j.fertnstert.2018.01.037

Vercellini, 2017, Toward minimally disruptive management of symptomatic endometriosis: Reducing low-value care and the burden of treatment, Expert Rev. Pharmacoecon. Outcomes Res., 18, 1, 10.1080/14737167.2018.1411803

Vercellini, 2018, Are combined hormonal contraceptives the neglected treatment for symptomatic endometriosis?, Fertil. Steril., 110, 61, 10.1016/j.fertnstert.2018.03.038

Harada, 2008, Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebo-controlled, double-blind, randomized trial, Fertil. Steril., 90, 1583, 10.1016/j.fertnstert.2007.08.051

Vinogradova, 2015, Use of combined oral contraceptives and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases, BMJ, 350, h2135, 10.1136/bmj.h2135

Manzoli, 2012, Oral contraceptives and venous thromboembolism: A systematic review and meta-analysis, Drug Saf., 35, 191

Lidegaard, 2012, Venous thrombosis in users of non-oral hormonal contraception: Follow-up study, Denmark 2001–2010, BMJ, 344, e2990, 10.1136/bmj.e2990

Lidegaard, 2011, Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–2009, BMJ, 343, d6423, 10.1136/bmj.d6423

Casper, 2017, Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills, Fertil. Steril., 107, 533, 10.1016/j.fertnstert.2017.01.003

Brion, F., Le Page, Y., Piccini, B., Cardoso, O., Tong, S.-K., Chung, B.-C., and Kah, O. (2012). Screening estrogenic activities of chemicals or mixtures in vivo using transgenic (cyp19a1b-gfp) zebrafish embryos. PLoS ONE, 7.

Speroff, 2000, The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt??) on the frequency and intensity of vasomotor symptoms, Menopause, 7, 383, 10.1097/00042192-200011000-00003

Bernuit, 2011, Female perspectives on endometriosis: Findings from the uterine bleeding and pain women’s research study, J. Endometr., 3, 73, 10.5301/JE.2011.8525

Chapron, 2011, Oral contraceptives and endometriosis: The past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis, Hum. Reprod., 26, 2028, 10.1093/humrep/der156

Vercellini, 2011, Oral contraceptives and risk of endo-metriosis: A systematic review and meta-analysis, Hum. Reprod. Update, 17, 159, 10.1093/humupd/dmq042

Brown, 2014, Endometriosis: An overview of cochrane reviews, Cochrane Database Syst. Rev., 2014, CD009590

Jensen, 2018, Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: A systematic review of the evidence, Fertil. Steril., 110, 137, 10.1016/j.fertnstert.2018.03.012

Buggio, 2017, Oral and depot progestin therapy for endometriosis: Towards a personalisez medicine, Expert Opin. Pharmacother., 18, 1569, 10.1080/14656566.2017.1381086

Donnez, 1987, Combined (hormonal and microsurgical) therapy in infertile women with endometriosis, Fertil. Steril., 48, 239, 10.1016/S0015-0282(16)59349-2

Donnez, 1996, Large ovarian endometriomas, Hum. Reprod., 11, 641, 10.1093/HUMREP/11.3.641

Donnez, 1988, Histologic study of ovarian endometriosis after hormonal therapy, Fertil. Steril., 49, 423, 10.1016/S0015-0282(16)59766-0

Donnez, 1990, Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserelin spray and buserelin implant, in the treatment of endometriosis associated infertility, Prog. Clin. Boil. Res., 323, 427

Donnez, 1990, Endometriosis-associated infertility: Evaluation of preoperative use of danazol, gestrinone, and buserelin, Int. J. Fertil., 35, 297

Mabrouk, 2017, Short-term histopathological effects of dienogest therapy on ovarian endometriomas: In vivo, nonrandomized, controlled trial, Gynecol. Endocrinol., 34, 399, 10.1080/09513590.2017.1405932

Vercellini, 2016, Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: A before and after study, Fertil. Steril., 105, 734.e3, 10.1016/j.fertnstert.2015.11.016

Kim, 2013, Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer, Endocr. Rev., 34, 130, 10.1210/er.2012-1043

Donnez, 2017, Partial suppression of estradiol: A new strategy in endometriosis management?, Fertil. Steril., 107, 568, 10.1016/j.fertnstert.2017.01.013

Ferrero, 2012, Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies, Arch. Gynecol. Obstet., 287, 447, 10.1007/s00404-012-2581-2

Razzi, 2007, Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 135, 188, 10.1016/j.ejogrb.2006.08.002

Cursino, 2017, Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission, Eur. J. Obstet. Gynecol. Reprod. Biol., 211, 108, 10.1016/j.ejogrb.2017.02.015

Donnez, 2016, Uterine fibroid management: From the present to the future, Hum. Reprod. Update, 22, 665, 10.1093/humupd/dmw023

Donnez, 2020, Hormone therapy for intramural myoma-related infertility from ulipristal acetate to GnRH an-tagonist: A review, Reprod. Biomed. Online, 41, 431, 10.1016/j.rbmo.2020.05.017

Donnez, 2020, Fibroids and medical therapy: Bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist, Fertil. Steril., 114, 739, 10.1016/j.fertnstert.2020.07.028

Barbieri, 1992, Hormone treatment of endometriosis: The estrogen threshold hypothesis, Am. J. Obstet. Gynecol., 166, 740, 10.1016/0002-9378(92)91706-G

Chwalisz, 2012, The hormonal profile of norethindrone acetate: Rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis, Reprod. Sci., 19, 563, 10.1177/1933719112438061

(2020, October 01). European Society of Human Reproduction and Embryology ESHRE Guideline for the Diagnosis and Treatment of Endome-Triosis. Available online: http://guidelines.endometriosis.org/index.html.

Brown, 2010, Gonadotrophin-releasing hormone analogues for pain associated with endometriosis, Cochrane Database Syst. Rev., 2010, CD008475

Dragoman, 2016, Research gaps identified during the 2014 update of the WHO medical eligibility criteria for contraceptive use and selected practice recommendations for contraceptive use, Contracept, 94, 195, 10.1016/j.contraception.2015.12.009

Donnez, 2004, Surgical management of endometriosis, Best Pract. Res. Clin. Obstet. Gynaecol., 18, 329, 10.1016/j.bpobgyn.2004.03.004

Donnez, 1994, Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment, Br. J. Obstet. Gynaecol., 101, 2, 10.1111/j.1471-0528.1994.tb13677.x

Ng, 2017, Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women, J. Clin. Endocrinol. Metab., 102, 1683, 10.1210/jc.2016-3845

Carr, 2014, Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density, Reprod. Sci., 21, 1341, 10.1177/1933719114549848

Diamond, 2014, Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study, Reprod. Sci., 21, 363, 10.1177/1933719113497292

Taylor, 2017, Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist, N. Engl. J. Med., 377, 28, 10.1056/NEJMoa1700089

Surrey, 2018, Long-term outcomes of elagolix in women with endometriosis: Results from two extension studies, Obstet. Gynecol., 132, 147, 10.1097/AOG.0000000000002675

Osuga, 2021, Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: A randomized, double-blind, place-bo-controlled study, Fertil. Steril., 115, 397, 10.1016/j.fertnstert.2020.07.055

Donnez, 2020, Treatment of endome-triosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: A randomized clinical trial, Fertil. Steril., 114, 44, 10.1016/j.fertnstert.2020.02.114

Pohl, 2020, Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—Delayed add-back onset does not improve bleeding pattern, Reprod. Sci., 27, 988, 10.1007/s43032-020-00172-z

Taylor, 2019, Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain, Pain Manag., 9, 497, 10.2217/pmt-2019-0010

Donnez, 2020, Gonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis, Fertil. Steril., 114, 640, 10.1016/j.fertnstert.2020.04.017

Lamb, 2018, Elagolix: First global approval, Drugs, 78, 1501, 10.1007/s40265-018-0977-4

Barra, 2019, Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain, Drugs Today, 55, 237, 10.1358/dot.2019.55.4.2930713

Pokrzywinski, 2020, Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials, Am. J. Obstet. Gynecol., 222, 592.e1, 10.1016/j.ajog.2019.11.1255

Taylor, 2020, Health-related quality of life improvements in patients with endometriosis treated with elagolix, Obstet. Gynecol., 136, 501, 10.1097/AOG.0000000000003917

Taylor, 2019, Long term treatment of endometriosis associated pain (EAP) with linzagolix: Efficacy and safety after 12 months of treatment, Fertil. Steril., 112, e323, 10.1016/j.fertnstert.2019.07.935

Bestel, 2020, Quality of life results after 52 weeks of treatment with linzagolix for endometriosis-associated pain, Obstet. Gynecol., 135, 26S, 10.1097/01.AOG.0000663200.75027.38

Donnez, 2019, What if deep endometriotic nodules and uterine adenomyosis were actually two forms of the same disease?, Fertil. Steril., 111, 454, 10.1016/j.fertnstert.2018.12.018

Borini, 2020, Gonadotropin-releasing hormone antagonist linzagolix: Possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis?, Fertil. Steril., 114, 517, 10.1016/j.fertnstert.2020.06.003

Markham, 2019, Relugolix: First global approval, Drugs, 79, 675, 10.1007/s40265-019-01105-0

Biberoglu, 1981, Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness, Am. J. Obstet. Gynecol., 139, 645, 10.1016/0002-9378(81)90478-6

Becker, 2020, Efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: Phase 3 randomized, double-blind, placebo-controlled study (spirit 2), Fertil. Steril., 114, e77, 10.1016/j.fertnstert.2020.08.238

Zandvliet, 2020, Simulated long-term effects of relugolix combination therapy on bone mineral density at the lumbar spine as predicted by a validated semi-mechanistic exposure-response model, Fertil. Steril., 114, e350, 10.1016/j.fertnstert.2020.08.1046

Practice Committee of the American Society for Reproductive Medicine (2018). American Society for Reproductive Medicine position statement on uterus transplantation: A committee opinion. Fertil. Steril., 110, 605–610.

Vercellini, 2019, Endometriosis Study, G. elagolix for endo-metriosis: All that glitters is not gold, Hum. Reprod., 34, 193, 10.1093/humrep/dey368

Donnez, 2017, Choosing the right surgical technique for deep endometriosis: Shaving, disc excision, or bowel resection?, Fertil. Steril., 108, 931, 10.1016/j.fertnstert.2017.09.006

Soliman, 2018, Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States, Adv. Ther., 35, 408, 10.1007/s12325-018-0667-3

Wang, 2019, Cost–effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA, J. Comp. Eff. Res., 8, 337, 10.2217/cer-2018-0124

Leyland, N., Estes, S.J., Lessey, B.A., Advincula, A.P., and Taylor, H.S. (2020). A clinician’s guide to the treatment of endometriosis with elagolix. J. Womens Heal.

Black, 2019, Assessing research gaps and unmet needs in endometriosis, Am. J. Obstet. Gynecol., 221, 86, 10.1016/j.ajog.2019.02.033